财经快讯|步长制药：拟委托北京维斯迈就宣肺败毒颗粒治疗甲型流感有关临床研究项目进行临床试验设计与实施
步长制药12月22日公告，公司与北京维斯迈医疗科技有限公司（简称“北京维斯迈”）签订《技术服务合同》，委托北京维斯迈就宣肺败毒颗粒治疗甲型流感的有效性和安全性的前瞻性、多中心、随机对照临床研究项目进行临床试验设计与实施。技术服务经费总额为1040.95万元。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
Related News
